A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2006
11/30/2006	US20060270643 Hyfroxyflutamide induced pathways related to androgen receptor negative prostate cancer cells
11/30/2006	US20060270642 Method and apparatus for transdermal or transmucosal application of testosterone
11/30/2006	US20060270641 Method for chemoprevention of prostate cancer
11/30/2006	US20060270640 Method of preventing, medicating, and/or treating hypocalcemia of domestic mammal
11/30/2006	US20060270639 Combinations of superoxide dismutase mimetics and nonsteroidal analgesic/anti-inflammatory drugs
11/30/2006	US20060270638 Delivery of tigecycline in the presence of warfarin
11/30/2006	US20060270637 Hydroxymethyl substituted dihydroisoxazole derivatives useful as antibiotic agents
11/30/2006	US20060270636 Methods for treatment of neuro- and nephro- disorders and therapeutic toxicities using aminothiol compounds
11/30/2006	US20060270635 Derivatives of 4- or 5-aminosalicylic acid
11/30/2006	US20060270634 Acetal phosphate-derived LPA mimics, PPARgamma activators, and autotaxin inhibitors
11/30/2006	US20060270633 Crystalline form of fosinopril calcium
11/30/2006	US20060270632 4-(2-Furoyl) aminopiperidine compound useful as therapeutic agent for itching
11/30/2006	US20060270631 Methods for the treatment and prevention of angiogenic diseases
11/30/2006	US20060270630 Methods for the treatment and prevention of inflammatory diseases
11/30/2006	US20060270629 5-bicyclo[3.1.0]hexanyl]pyrimidine-2,4-dione derivatives useful in the treatment or prevention of epilepsy, Parkinson's disease, Huntington's disease, respiratory system disorders, cancer and arrhythmias
11/30/2006	US20060270628 Antiinfective 1,2,3-triazole derivatives, process for their preparation and pharmaceutical compositions containing them
11/30/2006	US20060270627 Synthetic oligomannosides, preparation and uses thereof
11/30/2006	US20060270626 Crude exopolysaccharides produced from phellinus baumii mycelium having hypoglycemic activity and preparation method thereof
11/30/2006	US20060270625 Nutraceuticals for the treatment of neuropathy
11/30/2006	US20060270624 Gapped 2' modified oligonucleotides
11/30/2006	US20060270621 Inhibition of hair growth with RNAi targeting desmoglein 4 and nude mRNAs
11/30/2006	US20060270618 Novel pharmaceutical composition of interferon gamma or pirfenidone with molecular diagnostics for the improved treatment of interstitial lung diseases
11/30/2006	US20060270617 HkI10311129, novel antibiotic, method for producting the same and the use thereof
11/30/2006	US20060270616 Treating disorders of gastric motility; decreasing side effects of erythromycin A
11/30/2006	US20060270615 Compositions suitable for the treatment of damage caused by ischemia/reper-fusion or oxidative stress
11/30/2006	US20060270614 Use of chalcones for the treatment of viral disorders
11/30/2006	US20060270613 2,3,4,5,6-Pentahydroxyhexylamide of 4-(4-{4-[3-[3-(4-fluorophenyl)-3-hydroxypropyl]-2-(4-methoxyphenyl)-4-oxoazetidin-1-yl]benzylcarbamoyl}phenoxy)benzoic acid, for example; antilipemic agents; anticholesterol agents
11/30/2006	US20060270612 derivatives of pirfenidone which can modulate a stress activated protein kinase (SAPK) system; treatment of various inflammatory conditions and/or fibrotic conditions such as inflammatory pulmonary fibrosis and/or idiopathic pulmonary fibrosis
11/30/2006	US20060270611 Pediatric formulation of topiramate
11/30/2006	US20060270610 Novel compounds for hypoxic cell therapy and imaging
11/30/2006	US20060270608 Drugs for chronic pain
11/30/2006	US20060270607 Pharmaceutical combinations
11/30/2006	US20060270592 Use of neurotransmitters and neuropeptides for the treatment of dry eye diseases and related conditions
11/30/2006	US20060270590 Reduction in complement activation and inflammation during tissue injury by carotenoids, carotenoid analogs, or derivatives thereof
11/30/2006	US20060270589 Carotenoids, carotenoid analogs, or carotenoid derivatives for the treatment of visual disabilities
11/30/2006	US20060270588 Organic compounds
11/30/2006	US20060269959 Sequences of an Ih ion channel and use thereof
11/30/2006	US20060269956 Mutations in the Bcr-Abl tyrosine kinase associated with resistance to STI-571
11/30/2006	US20060269919 Method of diagnosis of obesity
11/30/2006	US20060269907 Decontamination of biological fluids using diphenylpyrilium compounds
11/30/2006	US20060269892 Methods and systems for enabling and stabilizing tooth movement
11/30/2006	US20060269632 Remedies for allergic diseases and process for producing the same
11/30/2006	US20060269628 Composition for attenuation of pain or wound healing agents in dosage
11/30/2006	US20060269627 Isolation of a Dual Cox-2 and 5-Lipoxygenase Inhibitor from Acacia
11/30/2006	US20060269622 Formulations and methods of administration of cephalotaxines, including homoharringtonine
11/30/2006	US20060269619 Nutrient system for individualized responsive dosing regimens
11/30/2006	US20060269618 Methods and compositions for treating Toxoplasma
11/30/2006	US20060269617 Supplement compositions and method of use for enhancement of insulin sensitivity
11/30/2006	US20060269616 Supplement composition and method of use for enhancement of DNA repair process
11/30/2006	US20060269613 Composition containing nanoparticles containing water-soluble basic drug encpsulated therein
11/30/2006	US20060269611 in males being treated for prostate cancer, with Toremifene or salts
11/30/2006	US20060269607 Timed, sustained release systems for propranolol
11/30/2006	US20060269604 Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
11/30/2006	US20060269603 Controlled release tramadol formulations
11/30/2006	US20060269602 A biocompatible, biodegradable polymer matrix, a drug and a bisphosphonate compound; increased length of time for sustained release; improved bioavailability
11/30/2006	US20060269601 Oral modified release formulations containing 8-prenylnaringenin for continuous estrogen support
11/30/2006	US20060269600 Enhancing bioavailability of oral immediate release tablets for low solubility medicants; respiratory inflammatory disorders
11/30/2006	US20060269599 Fast-dissolving pharmaceutical composition
11/30/2006	US20060269598 Antihistaminic/Decongestant/Anticholinergic Compositions and Methods of Use
11/30/2006	US20060269597 Tannate Compositions and Methods of Use for the Treatment of Respiratory Tract Conditions
11/30/2006	US20060269595 Liposomal antineoplastic drugs and uses thereof
11/30/2006	US20060269594 Liposomal antineoplastic drugs and uses thereof
11/30/2006	US20060269588 Safely controlling harmful rumen bacteria; cattle, poultry, horses, pigs, zoo animals
11/30/2006	US20060269587 Antisense restenosis composition and method
11/30/2006	US20060269581 Stable water in oil aminophylline emulsions
11/30/2006	US20060269579 Compositions for treating osteoarthritis
11/30/2006	US20060269578 Microemulsions and its use for preventing airway diseases
11/30/2006	US20060269551 Reducing interleukin (IL-20) induced inflammation by administering antibody, fragment or single chain antibody; adult respiratory disease, psoriasis, eczema, dermatitis, septic shock, multiple organ failure, pneumonia, inflammatory bowel disease, arthritis, asthma, ulcerative colitis, Crohn*s disease
11/30/2006	US20060269543 Compositions and methods for increasing the stability of antibodies
11/30/2006	US20060269539 Genetic engineering; Alzheimer's agents; anticancer agents
11/30/2006	US20060269535 Metallo-lactoferrin-coenzyme compositions for trigger and release of bioenergy
11/30/2006	US20060269530 RNA interference compositions and methods
11/30/2006	US20060269524 Composition for nkt cell activation
11/30/2006	US20060269517 Such as acarbose or castanospermine; interferons
11/30/2006	US20060269512 Non-lithotripsic kidney-stone therapy
11/30/2006	US20060269511 Multilayer binding; lamellar surface structure containing at least two binding compounds is assembled under conditions in which the binding compounds self-regulate in or on the lamellar structure; organized mobile multifunctional conjugate (OMMC) assembly
11/30/2006	US20060269510 Orlistat compositions
11/30/2006	US20060269504 Use of alkyl resorcinols in the treatment of acne
11/30/2006	US20060269500 Topical warming composition
11/30/2006	US20060269497 Trichogenous agent
11/30/2006	US20060269496 Applying to selected area of skin a dermatologically acceptable composition comprising a bile acid such as lithocholic acid, deoxycholic acid, or cholic acid in an amount effective to reduce hair growth, wherein bile acid is not ursodeoxycholic acid or chenodeoxycholic acid
11/30/2006	US20060269495 Alpha hydroxy acid compositions
11/30/2006	US20060269494 New Ubiquitin-Proteasome Regulating Compounds and Their Application in Cosmetic and Pharmaceutical Formulations
11/30/2006	US20060269487 Delivery of nonsteroidal antiinflammatory drugs through an inhalation route
11/30/2006	US20060269486 Anxiolytic agents; vaporization of thin film of diazepam
11/30/2006	US20060269484 Medicament formulations
11/30/2006	US20060269482 Cyclin-dependent kinase inhibition of Rb phosphorylation
11/30/2006	US20060269480 Multi-triggered self-immolative dendritic compounds
11/30/2006	US20060269479 Amphiphilic polymers and methods of use thereof
11/30/2006	DE60119082T2 Anästhetikum enthaltende formulierungen Anesthetic formulations containing
11/30/2006	DE202006013847U1 Alpha-liponic acid composition, useful e.g. in the treatment of diabetic retinopathy, comprises chromic compound and isoflavon(e)
11/30/2006	DE19781703B4 Gegen Tumoren wirksame Anthracyclindisaccharide, Fermentationsverfahren zu deren Herstellung und diese enthaltende therapeutische Zusammensetzung Effective against tumors Anthracyclindisaccharide, fermentation processes for their preparation and therapeutic composition containing them
11/30/2006	DE10392416B4 Blutstillender Verband Hemostatic dressing
11/30/2006	DE102005038947A1 Substituierte Benzo[d]isoxazol-3-yl-amin-Verbindungen und deren Verwendung in Arzneimitteln Substituted benzo [d] isoxazol-3-yl-amine compounds and their use in medicaments
11/30/2006	DE102005024494A1 Verwendung von Cyanopyrimidinen Use of Cyanopyrimidinen
11/30/2006	DE102005024493A1 Verwendung von Pyrazolopyrimidinen Use of pyrazolopyrimidines
11/30/2006	DE102005024245A1 Thienopyridine Thienopyridines
11/30/2006	DE102005024017A1 Chinazolinone Quinazolinones
11/30/2006	CA2645647A1 Compositions containing pufa and/or uridine and methods of use thereof
11/30/2006	CA2645645A1 Compositions containing pufa and methods of use thereof

1 ... 3986 3987 3988 3989 3990 3991 3992 3993 3994 3995 3996 3997 3998 3999 4000 4001 4002 4003 4004 4005 4006 ... 7860